מדינה: הממלכה המאוחדת
שפה: אנגלית
מקור: MHRA (Medicines & Healthcare Products Regulatory Agency)
Hepatitis B immunoglobulin human
Biotest (UK
Hepatitis B immunoglobulin human
500iu/1ml
Solution for injection
Subcutaneous
No Controlled Drug Status
Valid as a prescribable product
BNF: ; GTIN: 04036124018399
1 PACKAGE LEAFLET 2 PACKAGE LEAFLET: INFORMATION FOR THE USER ZUTECTRA 500 IU SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE Human hepatitis B immunoglobulin READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Zutectra is and what it is used for 2. What you need to know before you use Zutectra 3. How to use Zutectra 4. Possible side effects 5. How to store Zutectra 6. Contents of the pack and other information 7. How to inject Zutectra by yourself or by caregiver 1. WHAT ZUTECTRA IS AND WHAT IT IS USED FOR WHAT ZUTECTRA IS Zutectra contains antibodies against the hepatitis B virus which are the body's own defensive substances to protect you from hepatitis B. Hepatitis B is an inflammation of the liver caused by the hepatitis B virus. WHAT ZUTECTRA IS USED FOR Zutectra is used to prevent re-infection of hepatitis B in adults who have had a liver transplant at least 1 week ago because they had liver failure caused by hepatitis B. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE ZUTECTRA DO NOT USE ZUTECTRA - if you are allergic to human immunoglobulin or any of the other ingredients of this medicine (listed in section 6). An allergic reaction may include sudden wheeziness, difficulty in breathing, fast pulse, swelling of the eyelids, face, lips, throat or tongue, rash or itching. Zutectra is for subcutaneous (under the skin) injection only. Injection into a vein or a blood vessel may result in allergic shock. WARNINGS AND PRECAUTIONS PLEASE TELL YOUR DOCTOR OR HEALTHCARE PROFESSIONAL PRIOR TO TREATMENT - if you קרא את המסמך השלם
OBJECT 1 ZUTECTRA Summary of Product Characteristics Updated 05-Jan-2016 | Biotest (UK) Ltd 1. Name of the medicinal product Zutectra 500 IU solution for injection in pre-filled syringe 2. Qualitative and quantitative composition One pre-filled syringe of 1 ml contains Human hepatitis B immunoglobulin 500 IU. Human protein 150 mg/ml of which at least 96 % is IgG, with a content of antibodies to hepatitis B virus surface antigen (HBs) of 500 IU/ml. Distribution of IgG subclasses: IgG1: IgG2: IgG3: IgG4: 59 % 35 % 3 % 3 % IgA content max. 6,000 micrograms/ml. For the full list of excipients, see section 6.1. 3. Pharmaceutical form Solution for injection (injection). The solution is clear and pale yellow or light brown. 4. Clinical particulars 4.1 Therapeutic indications Prevention of hepatitis B virus (HBV) re-infection in HBsAg and HBV-DNA negative adult patients at least one week after liver transplantation for hepatitis B induced liver failure. HBV-DNA negative status should be confirmed within the last 3 months prior to OLT. Patients should be HBsAg negative before treatment start. The concomitant use of adequate virostatic agents should be considered as standard of hepatitis B re- infection prophylaxis. 4.2 Posology and method of administration Posology In HBV-DNA negative adults at least one week after liver transplantation subcutaneous injections of Zutectra per week or fortnightly according to serum anti-HBs trough levels. Prior to the initiation of subcutaneous treatment with Zutectra adequate anti-HBs serum levels should be stabilised with an intravenous hepatitis B immunoglobulin to levels at or above 300-500 IU/l in order to ensure adequate anti-HBs coverage during the transition from intravenous to subcutaneous dosing. Antibody levels >100 IU/l should be maintained in HBsAg and HBV-DNA negative patients. The dose can be individually established and adapted from 500 IU up to 1,000 IU (in exceptional cases up to 1,500 IU) subcutaneous injections on a weekly or fortnightly basis, according to the serum an קרא את המסמך השלם